Table 6.

RET gene fusions inhibitors in clinical trials [40]

Clinicaltrials.gov identifier	Study agent	Trial Phase	Trial description
NCT01639508	Cabozantinib	Phase II	Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
NCT04194944	Selpercatinib vs Carboplatin/Cisplatin + Pemetrexed ± Pembrolizumab	Phase III	A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431)
NCT04268550	Selpercatinib	Phase II	Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
NCT04131543	Cabozantinib	Phase II	Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA)
NCT03037385	Pralsetinib (BLU-667)	Phase I/II	Phase I/II Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)
NCT04222972	Pralsetinib vs Carboplatin/Cisplatin + Pemetrexed ± Pembrolizumab or Carboplatin/Cisplatin Gemcitabine (Squamous histology)	Phase III	AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive, Metastatic NSCLC
NCT04683250	TAS0953/HM06	Phase I/II	Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities ((MARGARET))
NCT03780517	BOS172738	Phase I	Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors
NCT03157128	LOXO-292 (Selpercatinib)	Phase I/II	Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
NCT04161391	TPX-0046	Phase I/II	Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations